The subgroup of patients with KRAS mutations detected in both plasma and matched tumor tissue (pMUT-tMUT) showed shorter PFS (p = 0.042) and a trend for shorter OS (p = 0.062) compared to patients with single specimen mutations (pMUT-tWT and pWT-tMUT) and patients that were KRAS G12/G13 wild type in both samples (pWT-tWT) (Figure S2). Here, KRAS is linked to neoplasm.